Comgest Global Investors S.A.S. Grows Holdings in Zoetis Inc. $ZTS

Comgest Global Investors S.A.S. increased its stake in Zoetis Inc. (NYSE:ZTS) by 2.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,453,966 shares of the company’s stock after acquiring an additional 36,238 shares during the period. Zoetis makes up approximately 3.8% of Comgest Global Investors S.A.S.’s investment portfolio, making the stock its 10th biggest position. Comgest Global Investors S.A.S. owned approximately 0.33% of Zoetis worth $212,744,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares in the last quarter. Empowered Funds LLC grew its holdings in Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the period. Intech Investment Management LLC raised its position in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Chicago Partners Investment Group LLC boosted its position in shares of Zoetis by 67.0% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock valued at $750,000 after purchasing an additional 1,961 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 2.9%

Shares of NYSE ZTS opened at $129.17 on Thursday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The business has a 50-day moving average price of $125.01 and a two-hundred day moving average price of $135.02. The firm has a market capitalization of $54.53 billion, a PE ratio of 21.46, a PEG ratio of 1.92 and a beta of 0.96.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The firm’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research note on Thursday, December 18th. Bank of America upped their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Piper Sandler reissued a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Barclays started coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.